Pfizer's JAK1 inhibitor abrocitinib is approved in the EU for the treatment of moderate to severe atopic dermatitis

CompilationFan Dongdong

A few days ago, Pfizer said in a statement on Friday that the European Commission has approved 100 mg and 200 mg doses of Cibinqo (abrocitinib) for the treatment of moderate to severe atopic dermatitis in adults suitable for systemic therapy

Cibinqo's approval is mainly based on the results of five clinical studies conducted on more than 2,800 patients, including four phase 3 studies and an ongoing long-term open label extension study

The JADE MONO-1 and JADE MONO-2 trials are a pair of randomized, double-blind, placebo-controlled studies designed to evaluate the two doses (100 mg and 200 mg, once a day) of Cibinqo monotherapy in 778 patients for 12 years.

In addition, Cibinqo also demonstrated consistent safety characteristics derived from multiple trials, including in long-term extended studies, showing favorable benefit-risk characteristics

Cibinqo is an oral small molecule that can selectively inhibit Janus kinase (JAK)1

Reference source:

1.

2.